REGN

Regeneron Pharmaceuticals
D

REGN

Arincen73/100B
904.38
USD
1.56
(0.17%)
Pre Open·910.20USD+5.82(+0.64%)
Last updated: · Delayed 15 min
Fair value814.64Plus+11%346Price 904.381,431
Q4 FY2026 · Earnings report
EPS estimate 25.39Revenue estimate 5.85B
OverviewFinancialsForecastEarningsDividendsCompany

Regeneron Pharmaceuticals total debt 1990–2026

Regeneron Pharmaceuticals's total debt was 2.71B USD on 30 September 2026, up 0.1% on a year before. At the end of fiscal year 2025 it was 2.71B USD.

Last updated 6 Nov 2026 · Next report 28 Jan 2027

Total debt

Growth

Fiscal yearPeriod endingTotal debtGrowthCash and short-term investmentsNet cashDebt to equity
Latest quarter30 Sept 20262.71B+0.06%9.30B6.59B0.08
FY202531 Dec 20252.71B+0.06%8.61B5.90B0.09
FY202431 Dec 20242.70B+0.06%9.01B6.31B0.09
FY202331 Dec 20232.70B+0.06%10.84B8.14B0.10
FY202231 Dec 20222.70B+0.06%7.74B5.04B0.12
FY202131 Dec 20212.70B+0.15%5.69B3.00B0.14
FY202031 Dec 20202.70B+277.60%3.59B891.30M0.24
FY201931 Dec 2019713.90M+0.76%3.21B2.50B0.06
FY201831 Dec 2018708.50M+0.72%2.81B2.10B0.08
FY201731 Dec 2017703.45M+46.21%1.41B706.13M0.11
FY201631 Dec 2016481.13M+28.13%1.04B557.56M0.11
FY201531 Dec 2015375.51M-18.20%1.05B669.71M0.10
FY201431 Dec 2014459.06M-9.19%900.48M441.42M0.18
FY201331 Dec 2013505.51M+10.54%693.98M188.47M0.26
FY201231 Dec 2012457.33M+5.00%308.10M-149.23M0.37
FY201131 Dec 2011435.53M+172.16%526.94M91.41M0.90
FY201031 Dec 2010160.03M+46.79%249.37M89.34M0.30
FY200931 Dec 2009109.02M+2,040.62%341.33M232.31M0.27
FY200831 Dec 20085.09M-97.48%474.75M469.66M0.01
FY200731 Dec 2007202.29M+1.15%766.46M564.17M0.44
FY200631 Dec 2006200.00M0.00%459.28M259.28M0.92
FY200531 Dec 2005200.00M0.00%298.55M98.55M1.75
FY200431 Dec 2004200.00M-6.46%295.98M95.98M1.10
FY200331 Dec 2003213.82M+6.83%293.77M79.96M1.55
FY200231 Dec 2002200.15M-0.21%264.27M64.12M1.37
FY200131 Dec 2001200.58M+7,381.39%385.08M184.50M0.75
FY200031 Dec 20002.68M-34.61%117.61M114.93M0.01
FY199931 Dec 19994.10M-2.38%66.20M62.10M0.04
FY199831 Dec 19984.20M-25.00%19.80M15.60M0.03
FY199731 Dec 19975.60M-35.63%28.90M23.30M0.04
FY199631 Dec 19968.70M-8.42%34.50M25.80M0.08
FY199531 Dec 19959.50M-22.76%32.70M23.20M0.14
FY199431 Dec 199412.30M+64.00%23.60M11.30M0.18
FY199331 Dec 19937.50M+10.29%12.50M5.00M0.08
FY199231 Dec 19926.80M+142.86%16.40M9.60M0.08
FY199131 Dec 19912.80M—26.20M23.40M0.03
FY199031 Dec 19900.00—21.80M21.80M0.00

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

Total debt counts commercial paper, term debt and lease liabilities.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Free cash flow,Stock buybacks,Balance sheet

Common questions about Regeneron Pharmaceuticals's debt

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.